🦵 Knee Stem Cell Therapy in Dubai at a Glance
🧬 What Is Knee Stem Cell Therapy?
Knee stem cell therapy is a broad term for cell-containing treatments used with the aim of improving symptoms or influencing the biological environment inside an osteoarthritic knee.
The important word is broad.
Two treatments can both be marketed as “stem cell therapy” while involving very different biological products.
One may use bone marrow collected and concentrated during the same procedure.
Another may use cells obtained from adipose tissue. A third may involve mesenchymal stromal cells, or MSCs, that have been expanded in a laboratory.
Those differences affect the procedure, evidence, regulation, and price.
🔬 Why can “stem cell therapy” mean different treatments?
The main categories you may encounter include:
- bone marrow aspirate concentrate, or BMAC
- adipose-derived stromal vascular fraction, or SVF
- culture-expanded MSCs
- donor-derived MSC products
They should not be treated as interchangeable simply because they appear under the same regenerative-medicine label.
A better first question is:
What exact cell or tissue preparation would be injected into my knee?
Once you know that, the evidence, dose, regulatory status, and price become much easier to evaluate.
📊 Does Stem Cell Therapy Work for Knee Osteoarthritis?
Some cell-based therapies may improve knee osteoarthritis pain and function, but the size and certainty of the benefit vary considerably between studies and treatments.
A 2025 Cochrane review identified 25 randomized trials involving 1,341 participants. In placebo-controlled studies, stem cell injections may slightly improve pain and function over approximately three to six months, but Cochrane rated the evidence as low certainty.²
A 2026 systematic review and meta-analysis of 28 randomized controlled trials also found improvements in several measures of pain and function. However, results varied by cell preparation, source, comparator, follow-up period, and study design.³
🩹 What does the research show about pain?
Pain reduction is one of the more consistent signals in the current evidence.
In the Cochrane placebo comparison, patients receiving stem cell injections experienced approximately 1.2 points greater improvement on a 0–10 pain scale at around six months.²
For someone struggling with stairs, walking, exercise, golf, or day-to-day mobility, an improvement in symptoms can be meaningful.
But an average effect across a study cannot predict what one individual patient will experience.
🚶 What does the evidence show about function?
Function may also improve.
The Cochrane analysis reported an estimated improvement of approximately 14 points on a 0–100 functional scale compared with placebo at around six months, again based on low-certainty evidence.²
The 2026 meta-analysis also reported significant improvements in selected KOOS domains, including activities of daily living, sports, pain, and symptoms, although not every measured outcome favored MSC treatment.³
🧩 Why do results differ between studies?
“Knee stem cell therapy” groups together interventions that can differ in almost every clinically relevant way.
Research varies by:
- tissue source
- autologous versus donor-derived cells
- point-of-care versus culture-expanded preparations
- cell dose
- viability and manufacturing
- single versus repeated injections
- OA severity
- patient age and BMI
- injection technique
- rehabilitation
- use of PRP or other adjunct treatments
That is why a positive result from one MSC trial should not automatically be used to support a substantially different commercial protocol.
🔗 Read more → Stem Cell Therapy Success Rate: What the Evidence Actually Shows
🧱 Can Stem Cells Regrow Knee Cartilage?
Current clinical evidence does not show that stem cell injections reliably regrow lost knee cartilage in people with osteoarthritis.
This distinction matters because “regeneration” is one of the most attractive claims in regenerative-medicine marketing.
Cochrane found potential improvements in pain and function but remained uncertain about the effect of treatment on structural progression.²
The 2026 analysis of 28 randomized trials found no significant improvement in MRI-based WORMS structural scores, despite improvements in several symptomatic outcomes.³
🔎 Symptom improvement is not the same as cartilage regeneration
A person can experience:
- less pain
- easier walking
- improved function
- greater tolerance for exercise
without meaningful new articular cartilage being demonstrated.
That does not make the improvement unimportant.
It simply means feeling better and structurally regenerating the knee are different outcomes.
If cartilage regrowth is specifically being promised, ask what human evidence supports that claim for the particular product and protocol being offered.
📋 What Does the Evidence Actually Support?
👤 Who May Be a Candidate for Knee Cell Therapy?
Selected patients with a confirmed knee osteoarthritis diagnosis and persistent symptoms despite appropriate non-operative care may be reasonable candidates for further evaluation.
Candidacy cannot be determined from an X-ray grade alone.
An important qualification is that the 2026 ESSKA-ICRS recommendations apply specifically to intra-articular point-of-care cell-based therapy, rather than every culture-expanded or donor-derived MSC product.⁵
The consensus evaluated 144 clinical scenarios using age, BMI, OA severity, joint compartment, and whether the point-of-care preparation came from bone marrow or adipose tissue.
Only 11.8% of scenarios were considered appropriate, while 53.5% were uncertain and 34.7% inappropriate.⁵
🩻 How much does osteoarthritis grade matter?
The Kellgren-Lawrence scale is commonly used to describe knee OA on X-rays.
In simplified terms:
- Grade I: early or doubtful changes
- Grade II: mild but definite osteoarthritis
- Grade III: moderate structural disease
- Grade IV: severe osteoarthritis
In the 2026 consensus, KL Grade II–III scenarios had the highest proportion rated appropriate.
Grade IV generated considerably more inappropriate scenarios.⁵
But OA grade is still only one part of the decision.
A proper orthopedic evaluation may also consider alignment, meniscus damage, ligament stability, pain pattern, inflammatory disease, previous surgery, body weight, physical activity, and treatments already attempted.
🦴 What about bone-on-bone knee arthritis?
Advanced or “bone-on-bone” osteoarthritis does not make symptom improvement impossible, but expectations generally need to be more conservative.
In the 2026 point-of-care consensus, 62.5% of KL Grade IV scenarios were considered inappropriate.⁵
Cell therapy also cannot mechanically straighten a severely deformed knee, restore a missing meniscus, correct major instability, or reliably reconstruct a severely damaged joint surface.
For advanced OA, understanding surgical options remains important even when the goal is to avoid surgery.
⚙️ Is the main problem biological or mechanical?
This is a useful question to discuss with an orthopedic specialist.
An injection may influence inflammation or the biological environment within the joint.
It cannot correct every mechanical cause of knee pain.
If major malalignment, instability, structural collapse, or another mechanical problem is driving symptoms, treating only the biological environment may leave the main problem unresolved.
🧭 Where Does Cell Therapy Fit in Knee Osteoarthritis Treatment?
Cell-based therapy is better viewed as one possible step within a broader knee osteoarthritis treatment pathway, rather than the automatic first treatment after diagnosis.
A 2025 ESSKA-ORBIT consensus involving experts in musculoskeletal regenerative medicine concluded that cell-based therapies may provide pain and functional benefit.
But it should not currently be considered a first-line injectable treatment because evidence remains heterogeneous and superiority over other injectables has not been consistently demonstrated.⁴
A typical treatment pathway may include:
diagnosis → exercise and rehabilitation → weight management where relevant → medication or conventional care → appropriate injectable therapies → selected regenerative options → surgical evaluation where indicated
It is also important to understand how professional recommendations have evolved.
The 2019 ACR/Arthritis Foundation guideline, published in 2020, strongly recommended against stem cell injections for knee and hip OA, citing heterogeneity and lack of standardization.⁷
In 2022, NICE considered intra-articular stem cell treatment experimental and recommended further research.⁸
More recent 2025–2026 orthopedic consensus statements are somewhat more permissive for carefully selected patients, while still emphasizing uncertainty and the lack of a standardized first-line role.⁴˒⁵
These positions are not necessarily contradictory. They reflect an evidence base that continues to develop while major questions around product standardization, patient selection, and comparative effectiveness remain unresolved.
⚖️ Is Knee Stem Cell Therapy Legal in Dubai?
Certain cell-based orthopedic procedures can be provided within Dubai's current regulatory framework, but there is no blanket authorization covering every treatment marketed as “stem cell therapy.”
Dubai Health Authority's Standards for Stem Cell Services were issued on December 31, 2025 and became effective on February 28, 2026.¹ The standards distinguish therapies according to cell source, manipulation, intended use, and regulatory category.
🇦🇪 What do the DHA standards say about knee osteoarthritis?
The DHA standards specifically list localized osteoarthritis and cartilage injury under orthopedic surgery, including same-day autologous SVF within the defined indication framework.¹
The standards also describe qualifying bone marrow aspirate concentrated into BMAC without cell expansion among examples of minimally manipulated autologous products.¹
That does not mean every product described as BMAC, SVF, MSC therapy, or “stem cells” automatically has the same regulatory status.
How the biological material is processed matters.
🧪 Why are minimally manipulated and culture-expanded cells different?
A same-day point-of-care preparation may undergo limited processing such as washing, filtration, centrifugation, or mechanical separation.
Culture expansion is fundamentally different because cells are grown outside the body before administration.
Under DHA's framework, substantial manipulation, including ex vivo MSC expansion, moves the treatment into the investigational or clinical-trial pathway rather than the routine minimally manipulated category.¹
🧬 Why are donor-derived MSC products different?
Allogeneic cells come from another person.
These products can involve a different regulatory route from same-day autologous orthopedic procedures, particularly when they are manufactured biological products. UAE federal product classification and marketing authorization may also involve the Emirates Drug Establishment, depending on the product.⁹
📋 Dubai Knee Cell Therapy: Regulatory Snapshot
🔗 Read more → Is Stem Cell Therapy Legal in Dubai? 2026 DHA Rules Explained
🔬 What Types of Knee Cell Therapy Are Used?
The main cell-based approaches differ enough that understanding the terminology can prevent misleading comparisons.
🦴 What is BMAC?
Bone marrow aspirate concentrate, or BMAC, is a point-of-care preparation made by collecting a patient's own bone marrow and concentrating it before administration.
It contains a mixture of cells and signaling components rather than a purified population of culture-expanded MSCs.
Under Dubai's current framework, BMAC without expansion can fall within examples of minimally manipulated autologous products when the applicable requirements are met.¹
🧫 What is adipose-derived SVF?
Stromal vascular fraction, or SVF, is a mixed cellular fraction obtained from adipose tissue.
Its regulatory classification depends heavily on how the tissue is processed.
Dubai's standards distinguish qualifying mechanically processed same-day preparations from more substantially manipulated approaches.¹
🧬 What are culture-expanded MSCs?
Culture-expanded mesenchymal stromal cells are cells that have been isolated and grown outside the body to increase their number before administration.
That can produce a more defined cellular product, but it also introduces additional manufacturing, quality-control, and regulatory requirements.
Under DHA rules, ex vivo cell expansion constitutes substantial manipulation.¹
📊 BMAC vs SVF vs Culture-Expanded MSCs
There is no universal winner.
The more useful question is whether the proposed product has a defensible rationale and evidence base for your knee and your stage of osteoarthritis.
⚔️ PRP vs Stem Cell Therapy for Knee Osteoarthritis
PRP and cell-based therapy are different orthobiologic treatments, and current evidence does not establish that cell therapy is universally superior.
PRP, or platelet-rich plasma, is produced from the patient's blood. It concentrates platelets and associated signaling molecules, but it is not a stem cell treatment.
The 2025 ESSKA consensus did not find sufficiently consistent superiority of cell-based treatment over other injectables to position it as the default first-line injectable option.⁴
This leads to an important principle:
More biologically complex does not automatically mean more clinically effective.
A physician recommending the more complex or expensive treatment should be able to explain why that added complexity is justified for your particular case.
💰 How Much Does Knee Stem Cell Therapy Cost in Dubai?
Knee stem cell therapy in Dubai can range from the high-thousands of dirhams for focused orthopedic procedures to AED 30,000+ (approximately USD $8,170+) for more involved regenerative programs. There is no reliable single Dubai average because the treatments being sold are not standardized.¹⁰
The STEMCIERGE Global Pricing Review currently draws on 692 regenerative-medicine pricing records across 10 countries. It reviews current provider pricing, treatment quotations, and market examples, then considers differences in treatment scope before producing planning ranges.¹⁰
Within current Dubai orthopedic observations reviewed by STEMCIERGE, focused procedures can begin around AED 7,500 (approximately USD $2,040), while more involved orthopedic programs can reach AED 30,000+ (approximately USD $8,170+). These are market observations for planning, not a Dubai-wide fee schedule, a treatment recommendation, or a personalized quote.¹⁰
USD conversions are approximate and can change with exchange rates.
🧾 Why is there no useful single average price?
Consider two hypothetical quotations.
Quote A: AED 8,000 (approximately USD $2,180)
Quote B: AED 25,000 (approximately USD $6,810)
The first appears much cheaper.
But perhaps Quote A covers one same-day autologous joint procedure, while Quote B includes another cellular product, bilateral treatment, multiple sessions, imaging, physician fees, and structured follow-up.
Until you know what sits behind each price, the numbers are not truly comparable.
🔗 Read more → Stem Cell Therapy Cost in Dubai: Pricing Guide
🔍 What usually changes the price?
Cost can vary according to:
- cell source and product type
- point-of-care versus culture-expanded processing
- one knee versus both knees
- number of sessions
- cell dose
- image guidance
- specialist and facility fees
- diagnostic imaging
- rehabilitation and follow-up
- additional orthobiologic procedures
Some quotations cover only the injection.
Others cover a broader treatment program.
Ask for enough detail to determine what is being administered, how many times, into which knee or knees, by whom, and what is included before and after treatment.
📑 How does STEMCIERGE build its pricing ranges?
The STEMCIERGE Global Pricing Review combines publicly available regenerative-medicine pricing, treatment quotations, and market examples across the countries we track. Records are assessed for treatment type and comparability so a focused orthopedic procedure is not silently treated as equivalent to a multi-day or multi-treatment program.¹⁰
Where pricing is too inconsistent to support a responsible range, it should be treated as a starting point rather than false precision.
🔗 Read more → Global Stem Cell Therapy Cost: Prices by Country & Treatment
🔢 Does Cell Dose and Product Quality Matter?
Yes, but more cells do not automatically mean a better knee treatment.
🧮 Does a higher stem cell dose mean better results?
A 2025 dose-focused meta-analysis included six randomized trials and 300 patients.
Doses of 25 million MSCs or fewer were associated with statistically significant improvement in the pooled analysis, while higher doses did not show additional benefit. Meta-regression found no significant dose-response relationship.⁶
That does not mean 25 million cells is the ideal dose.
It means current evidence does not support selecting a treatment simply because it advertises the largest number.
A 100-million-cell product is not automatically twice as effective as a 50-million-cell product.
Cell source, viability, manufacturing, administration route, treatment schedule, and patient selection all matter.
🔗 Read more → Stem Cell Dosage: Does a Higher Cell Count Mean Better Treatment?
🧫 What does cell viability tell you?
Cell count describes quantity.
It does not, by itself, establish product quality or clinical suitability.
For relevant cell products, DHA's current standards include quality considerations such as identity, sterility, viability, potency where applicable, and traceability.¹
The standards state that viability should generally be at least 70% at product release, unless another acceptance threshold is appropriately justified and validated.¹
That does not mean a product at 71% viability will work.
It illustrates a broader principle:
A cell dose without information about the product behind that number is incomplete information.
For a manufactured or expanded product, ask what quality and release information applies to the actual cells you would receive.
🩺 What Happens During Knee Stem Cell Treatment?
There is no single standard knee stem cell procedure. The process depends on the biological product and treatment strategy being used.
A well-structured treatment journey should begin long before the injection.
🔍 1. How should your knee be assessed?
The clinical team first needs to understand what is causing your symptoms.
Assessment may include:
- history and physical examination
- standing X-rays
- MRI when clinically appropriate
- OA grading
- alignment
- ligament and meniscus assessment
- previous surgery
- treatments already attempted
The goal is not merely to confirm that osteoarthritis exists.
It is to determine whether the proposed treatment makes sense for your particular knee.
🧭 2. How should the treatment strategy be explained?
A useful treatment recommendation should answer:
Why this treatment?
Why now?
Why this biological product?
Why not PRP, rehabilitation, another injection, continued conservative management, or surgical evaluation?
Good medical reasoning should remain understandable even when the science is complex.
🧬 3. How are cells or tissue obtained?
For autologous procedures, bone marrow or adipose tissue may be collected from the patient's own body.
Manufactured or donor-derived products follow a different pathway.
🧪 4. How is the biological material processed?
Processing can range from point-of-care concentration to much more extensive laboratory manufacturing.
This step matters because it can change both the final biological product and its regulatory classification.
💉 5. How is the treatment administered?
Most clinical research on cell-based treatment for knee OA involves intra-articular injection, meaning the product is administered directly into the joint.
Image guidance may be used depending on the procedure and protocol.
🏃 6. What is recovery like?
Recovery differs between a simple joint injection, a bone-marrow harvest, and an adipose-tissue harvest.
Temporary pain or swelling can occur after intra-articular MSC treatment, and harvest-based procedures can cause additional discomfort at the collection site.³
Before treatment, ask:
- when normal walking can resume
- when exercise can restart
- whether physiotherapy is recommended
- what activity restrictions apply
- whether medications need to be modified
- which symptoms require urgent medical review
Be cautious with universal promises such as “fully recovered in 48 hours.”
Recovery should reflect the actual procedure.
⏳ How Long Do Knee Stem Cell Results Last?
There is no reliable universal duration for the effects of knee stem cell therapy.
Many studies assess outcomes over approximately six to twelve months.
The 2025 ESSKA-ORBIT consensus describes clinically relevant benefits across this general timeframe while emphasizing that questions remain around long-term durability, optimal protocols, and repeat treatment.⁴
Some individual trials report longer follow-up.
That still does not justify promising every patient two, three, or five years of benefit.
If a proposed treatment comes with a specific durability claim, ask:
What long-term human evidence supports that estimate for this product and patient population?
⚠️ What Are the Risks and Limitations?
Cell-based knee therapies have generally shown a manageable short-term safety profile in clinical trials, but they are not risk-free, and important uncertainties remain.
The 2026 randomized-trial meta-analysis found higher rates of injection-site pain and joint swelling among MSC-treated patients.³
Cochrane found that serious adverse events were reported too infrequently to determine serious-harm risk confidently and noted that all invasive joint injections carry a small risk of septic arthritis.²
Depending on the procedure and product, potential concerns can include:
- temporary pain or swelling
- bruising or bleeding
- infection
- tissue-harvest discomfort
- inflammatory reactions
- donor- or product-specific risks
- uncertain long-term effectiveness
- financial loss if an expensive treatment provides little benefit
The risk profile of a same-day autologous preparation should not be assumed to be identical to that of a culture-expanded donor-derived product.
“Stem cell therapy” is too broad a label to describe one universal safety profile.
🇦🇪 What Knee MSC Research Is Underway in the UAE?
The UAE is participating in formal clinical research on mesenchymal stromal cell therapy for knee osteoarthritis, but these studies should not be used to validate unrelated commercial products.
A completed Phase I/II study in Abu Dhabi enrolled 12 adults with mild-to-moderate knee OA.
Participants received one ultrasound-guided intra-articular dose of 50 million allogeneic bone-marrow-derived MSCs. The study was open-label, single-arm, and designed primarily to assess safety and tolerability.¹¹ (
A larger Phase II/III study with an estimated 140 participants is now registered in Abu Dhabi, comparing the same investigational cell product with hyaluronic acid. The trial is recruiting and has an estimated completion date in 2027.¹¹
This is encouraging for the UAE's regenerative-medicine research ecosystem.
It also demonstrates an important scientific principle:
Evidence generated for one defined clinical-trial product cannot automatically be transferred to every MSC treatment offered commercially.
🔎 How Should You Evaluate a Knee Stem Cell Treatment in Dubai?
Do not evaluate a treatment primarily by luxury facilities, testimonials, price, or headline cell count. Start with the diagnosis and the medical rationale, then examine the actual protocol.
A credible proposal should allow you to answer:
- What is my exact diagnosis?
- Why am I considered a candidate?
- What cell or tissue preparation will be administered?
- Is it BMAC, SVF, culture-expanded MSCs, or something else?
- Is it autologous or donor-derived?
- What tissue source is used?
- How is the product processed?
- Has it been culture-expanded?
- What is the viable cell dose, where relevant?
- What human evidence supports this treatment for my type of knee OA?
- What regulatory pathway covers the treatment in Dubai?
- Who performs the procedure, and what follow-up is included?
Complex medicine will not always produce simple answers.
That is acceptable.
What matters is whether the medical team can explain the uncertainty clearly instead of replacing it with marketing language.
🚩 What red flags deserve a closer look?
Take extra care when you encounter:
- guaranteed cartilage regrowth
- promises to reverse osteoarthritis
- guaranteed avoidance of knee replacement
- very high “success rates” without clear methodology
- treatment recommendations before meaningful medical review
- the same protocol promoted for many unrelated conditions
- heavy emphasis on cell count without product characterization
- vague answers about cell source or processing
- “DHA approved” without explaining what is actually authorized
- no clear complication or follow-up pathway
- pressure to pay before medical candidacy has been established
A responsible provider should be able to explain what a treatment cannot reliably achieve as clearly as what it may potentially improve.
🔗 Read more → How to Compare International Stem Cell Treatments: Objective Evaluation Scorecard
✅ Is Knee Stem Cell Therapy Worth Considering?
For the right patient, a well-characterized cell-based treatment may be reasonable to investigate.
It should be approached as an option with potential benefits and genuine uncertainty, not as guaranteed knee regeneration.
It may deserve serious consideration when:
- your diagnosis is clearly established
- appropriate conservative care has already been considered
- the joint remains suitable for a non-surgical approach
- expectations focus on realistic outcomes such as pain and function
- the proposed product is clearly identified
- its regulatory status is transparent
- relevant human evidence supports the treatment strategy
- the financial cost is acceptable given the uncertainty
Greater skepticism is warranted when you are being sold:
Regeneration without evidence, a cell count without a meaningful product description, or a treatment package before your knee has been properly assessed.
The objective is not to find whoever promises the most.
It is to make the most defensible treatment decision for your knee.
🎯 Making a More Informed Decision About Knee Stem Cell Therapy in Dubai
Knee cell therapy sits in an important middle ground.
The evidence is encouraging enough to justify serious scientific and clinical interest. It is not strong enough to support many of the most ambitious claims used in regenerative-medicine marketing.
Three principles make the decision clearer:
Pain and function may improve, but reliable cartilage regrowth has not been demonstrated.
The words “stem cell therapy” tell you surprisingly little until the actual treatment product or preparation is identified.
A treatment should make sense as a complete protocol, including the patient, product, evidence, regulatory status, physician, procedure, and price.
If you are considering knee stem cell treatment in Dubai, STEMCIERGE can help you organize your case, understand the treatment options you are comparing, and identify important questions to resolve before choosing a provider.
Review your case with STEMCIERGE through our independent, patient-focused treatment decision process.
🔗 Read the FULL Dubai Guide → Stem Cell Therapy in Dubai, UAE: (Complete Guide)
❓ Frequently Asked Questions
How much does knee stem cell therapy cost in Dubai?
Current orthopedic market observations in the STEMCIERGE Global Pricing Review suggest that focused Dubai procedures can begin in the high-thousands of dirhams, while more involved programs may reach approximately AED 30,000+ (USD $8,170+).¹⁰ Final cost can change substantially with cell source, processing, number of knees, treatment sessions, imaging, medical fees, and follow-up.
Does stem cell therapy work for knee osteoarthritis?
Some randomized trials suggest that cell-based therapies may modestly improve pain and function in selected people with knee osteoarthritis. Evidence certainty remains limited, and outcomes vary across products and patient populations.²˒³
Can stem cells regrow knee cartilage?
Reliable human evidence that stem cell injections consistently regrow lost knee cartilage has not been established. Current research supports possible symptom improvement more strongly than structural regeneration.²˒³
Is knee stem cell therapy legal in Dubai?
Certain autologous, minimally manipulated orthopedic applications have defined pathways under current DHA standards. Culture-expanded and donor-derived MSC products may fall under different regulatory requirements and should be evaluated separately.¹
Is stem cell therapy better than PRP for knee arthritis?
Current evidence does not establish that cell-based therapy is universally superior to PRP. The 2025 ESSKA-ORBIT consensus does not position cell-based therapy as the default first-line injectable option.⁴ (
Can bone-on-bone knee arthritis be treated with stem cells?
Some patients with advanced OA may still experience changes in symptoms, but expectations should be cautious. In the 2026 point-of-care consensus, most Grade IV scenarios were considered either inappropriate or uncertain rather than clearly appropriate.⁵
How many stem cells are needed for knee osteoarthritis?
There is no universally established optimal cell number. Clinical trials have evaluated a wide range of doses, and a 2025 meta-analysis found no significant dose-response relationship.⁶
Can stem cell therapy prevent knee replacement?
There is not enough evidence to promise that cell-based therapy will prevent future knee replacement. Treatment may improve symptoms in selected patients, but whether it reliably alters long-term disease progression or the eventual need for surgery remains uncertain.²˒⁴
🔖 Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. Stem cell and other regenerative therapies may not be appropriate for every patient, and outcomes can vary based on diagnosis, disease severity, treatment type, cell product, and individual health factors. Always consult a qualified medical professional before making treatment decisions. Regulatory requirements, treatment availability, and pricing may change over time and should be verified directly with the relevant healthcare provider and regulatory authority.
📚 References
1. Dubai Health Authority. Standards for Stem Cell Services. Code DHA/HRS/HPSD/ST-68. Issue date: December 31, 2025. Effective date: February 28, 2026. DHA Standards for Stem Cell Services
2. Whittle SL, Johnston RV, McDonald S, et al. Stem cell injections for osteoarthritis of the knee. Cochrane Database of Systematic Reviews. 2025;4:CD013342. DOI: 10.1002/14651858.CD013342.pub2. Cochrane review
3. Awad G, Saad JP, Hamyeh A, Boutros M. Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Clinical Rheumatology. 2026;45(5):2905–2942. DOI: 10.1007/s10067-026-08042-w. PubMed record
4. de Girolamo L, Filardo G, Abat F, et al. The use of injectable orthobiologics for knee osteoarthritis: a formal ESSKA-ORBIT consensus. Part 2, Cell-based therapy. Knee Surgery, Sports Traumatology, Arthroscopy. 2025;33:4079–4095. DOI: 10.1002/ksa.70001. Full-text consensus
5. de Girolamo L, Kon E, Laver L, et al. Cell-based therapy injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy. 2026;34(8):3052–3065. DOI: 10.1002/ksa.70487. PubMed record
6. Rahmadian R, Ariliusra Z, Kusuma KRA, et al. Efficacy of a single intra-articular injection of mesenchymal stem cells for knee osteoarthritis: a dose-focused meta-analysis of randomized controlled trials. Journal of Orthopaedic Surgery and Research. 2025;20:812. DOI: 10.1186/s13018-025-06190-4. PubMed record
7. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care & Research. 2020;72(2):149–162. DOI: 10.1002/acr.24131. ACR/Arthritis Foundation guideline
8. National Institute for Health and Care Excellence. Osteoarthritis in over 16s: diagnosis and management. NICE Guideline NG226. Published 2022. NICE guidance and rationale
9. Emirates Drug Establishment. UAE product classification and marketing authorization services for pharmaceutical and biological products. EDE biological-product marketing authorization
10. STEMCIERGE. STEMCIERGE Global Pricing Review. Proprietary first-party analysis of regenerative-medicine pricing across 692 records and 10 countries, updated August 2026. Pricing is based on current provider pricing, treatment quotations, market examples, and treatment-context review. The underlying detailed database and methodology are proprietary. Global Stem Cell Therapy Cost Review
11. ClinicalTrials.gov. NCT06084988 and NCT07542808. UAE clinical studies evaluating intra-articular allogeneic bone-marrow-derived MSC therapy for knee osteoarthritis. Completed Phase I/II study Recruiting Phase II/III study
